Primary endpoints for safety and tolerability were met in Inovio Pharmaceuticals' Phase I clinical study evaluating its DNA immunotherapy candidate INO-1800 as a standalone treatment or combined with INO-9112 among 90 subjects with chronic hepatitis B infection. More data from the study will be submitted for publication and future medical conference presentation.
Cesca Therapeutics announced that a licensing agreement was signed between its subsidiary ThermoGenesis and IncoCell Tianjin to provide cellular processing services for chimeric antigen receptor T-cell therapies on a contract development and manufacturing basis to several Asia Pacific countries. Cesca will receive a percentage from IncoCell's gross contract development revenues.
A study in The Journal of Infectious Diseases found the Xpert HCV Viral Load Finger Stick, which uses finger-stick capillary blood samples to detect hepatitis C virus infections, had 100% sensitivity and specificity when tested on participants in Australia. Researchers found the assay can produce results in 60 minutes during a single clinical visit.
Gilead Sciences has named John McHutchison, executive vice president of clinical research, as its new chief scientific officer who will lead the company's research and development group, while Andrew Cheng, executive vice president of clinical R&D operations, will take on the role of chief medical officer. Both changes will take effect next month with the departure of Norbert Bischofberger as chief scientific officer and executive vice president of R&D.
The Securities and Exchange Commission has charged two executives from the blood startup Theranos -- Elizabeth Holmes, CEO and founder, and Ramesh "Sunny" Balwani, former president -- with fraud. The SEC alleges that the company misled investors about a blood-testing device that supposedly required only a few drops of blood for laboratory tests and that it exaggerated or falsified data regarding revenues and collaborations.
The FDA approved the investigational new drug application for Actinium Pharmaceuticals' Phase I trial for its candidate Actimab-A in combination with CLAG-M to treat relapsed or refractory acute myeloid leukemia. The trial will enroll 18 participants to assess the combination therapy's safety and efficacy in AML patients based on factors such as response rates, overall survival and the percentage of patients receiving a bone marrow transplant.
A 3-year-old Canadian girl from Nova Scotia will receive a cornea transplant in Toronto to repair a membrane in her right eye that has grown back repeatedly after surgical removal. Norah Cameron-Ranni was born with cataracts and developed glaucoma in both eyes, and her father says her left eye will likely need a cornea transplant in the future.
A 3-month-old who was born with Peters anomaly, a congenital condition in which the cornea is opaque, has received a corneal transplant. "Her lens is clear now, and her retina too is normal, and we expect her to have about 60 to 70% vision in the operated eye," said Dr. Mohan Rajan of Rajan Eye Care Hospital in Chennai, India.
Dengue fever patients had an increased risk of strokes, particularly in the first two months after diagnosis, according to a study in the Canadian Medical Association Journal. The analysis of data from the Taiwan National Health Insurance Research Database showed 13,787 patients with dengue fever or dengue hemorrhagic fever had 5.33 cases of stroke per 1,000 person-years, compared with 3.72 cases per 1,000 person-years among matched controls.
Living kidney donations by men declined 25% from 2005 to 2015, while donations by women dropped 5%, according to a study in the Journal of the American Society of Nephrology. The potential loss of two months' worth of income was a key factor in the decline, researchers said.
- Page 1